UTD1
Phase 2Small molecule
UTD1 is one of 78 small molecule programs targeting Neoadjuvant Therapy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
UTD1
HHunan Cancer Hospital
Phase 2
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UTD1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHunan Cancer Hospital